Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: A randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201704002167269

Enrollment

140

Registered

2017-04-02

Start date

2016-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-menopausal vaginal atrophy

Interventions

oxytocin vaginal gel

Methyl Cellulose (Placebo)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: ¿ Healthy postmenopausal women (at least two years after menopause) who were suffering from symptoms of vaginal atrophy (such as vaginal dryness, pain, itching, discomfort and bleeding during intercourse). ¿ Had not used any estrogen or other hormonal treatments (systemic or topical) during a four-week period prior to the trial.

Exclusion criteria

Exclusion criteria: ¿ Any chronic illnesses. ¿ Allergy to oxytocin or cellulose.

Design outcomes

Primary

Measure	Time frame
¿Visual and colposcopic changes in vaginal mucosa ;¿Histopathological evaluation of punch biopsy of the vaginal mucosa ;Symptoms (Dyspareunia & soreness)	—

Secondary

Measure	Time frame
¿ Serum level of estradiol	—

Countries

Egypt

Contacts

Public ContactAsem A. Moussa

Professor of obstetrics & gynecology- Al-Azhar University

dramoussa77@hotmail.com+201001414226

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026